10-Q quarterly report · filed Nov 5, 2026

BioAge Labs, Inc. (BIOA) Q3 2026 10-Q Quarterly Report

Short answer

BioAge Labs, Inc. (BIOA) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $298,000 (down 85.5% year over year) with net income of −$34M.

Q3 2026 key financials · XBRL

Revenue
$298,000
−85.5% YoY · −87.8% QoQ
Net income
−$34M
−66.1% YoY · −28.4% QoQ
Operating margin
-12554.0%
EPS (diluted)
−$0.73
−30.4% YoY · −23.7% QoQ

Source: XBRL data from the BioAge Labs, Inc. (BIOA) Q3 2026 10-Q on SEC EDGAR. USD.

BioAge Labs, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Collaboration revenue $0.3M, down 85% YoY from $2.1M, reflecting a $1.7M Novartis catch-up adjustment
  • Net loss $33.5M vs $20.2M YoY, with operating expenses $37.7M vs $25.2M
  • BGE-102 R&D spending $17.8M vs $4.7M, the strongest program; other programs $4.4M vs $7.7M
  • Cash, equivalents and marketable securities $352.3M; operating cash used $74.3M through nine months
  • Funding expected through 2029; QUELL-CV topline data anticipated fourth quarter 2026, with additional capital needs and clinical risks remaining

Risk Factors

  • Newly added regulatory risk: BIOSECURE Act, triggered by WuXi AppTec’s June 8, 2026 designation on the 1260H List
  • Most material update: QUELL-DME began dosing approximately 180 participants, including combination therapy with anti-VEGF
  • Near-term clinical risk: QUELL-CV topline data anticipated in fourth quarter of 2026, with hsCRP reduction potentially not translating into cardiovascular benefit
  • Financial risk: $352.3 million in cash, equivalents and marketable securities expected to fund operations through 2029
  • Manufacturing risk: China and India suppliers exposed to tariffs, trade restrictions and supply-chain disruption

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other BioAge Labs, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.